264 related articles for article (PubMed ID: 29220539)
1. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma.
Zhang H; Li XX; Yang Y; Zhang Y; Wang HY; Zheng XFS
Hepatology; 2018 Jun; 67(6):2271-2286. PubMed ID: 29220539
[TBL] [Abstract][Full Text] [Related]
2. Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression.
Dauki AM; Blachly JS; Kautto EA; Ezzat S; Abdel-Rahman MH; Coss CC
Cancer Res; 2020 Feb; 80(3):561-575. PubMed ID: 31685543
[TBL] [Abstract][Full Text] [Related]
3. Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling.
Zhao J; Sun Y; Lin H; Chou F; Xiao Y; Jin R; Cai X; Chang C
FASEB J; 2020 Apr; 34(4):5877-5891. PubMed ID: 32134529
[TBL] [Abstract][Full Text] [Related]
4. A selective androgen receptor modulator, S4, displays robust anti-cancer activity on hepatocellular cancer cells by negatively regulating PI3K/AKT/mTOR signalling pathway.
Yavuz M; Takanlou LS; Avcı ÇB; Demircan T
Gene; 2023 Jun; 869():147390. PubMed ID: 36990257
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
6. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma.
Song H; Sun N; Lin L; Wei S; Zeng K; Liu W; Wang C; Zhong X; Wang M; Wang S; Zhou B; Lv C; Liu W; Zhao Y
Cancer Sci; 2020 Oct; 111(10):3665-3678. PubMed ID: 32745318
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
8. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor Stimulates Hexokinase 2 and Induces Glycolysis by PKA/CREB Signaling in Hepatocellular Carcinoma.
Sun RF; Zhao CY; Chen S; Yu W; Zhou MM; Gao CR
Dig Dis Sci; 2021 Mar; 66(3):802-813. PubMed ID: 32274668
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
11. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
12. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
13. Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion.
Ao J; Meng J; Zhu L; Nie H; Yang C; Li J; Gu J; Lin Q; Long W; Dong X; Li C
Mol Oncol; 2012 Oct; 6(5):507-15. PubMed ID: 22819717
[TBL] [Abstract][Full Text] [Related]
14. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Lu X; Paliogiannis P; Calvisi DF; Chen X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
17. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells.
Jie X; Lang C; Jian Q; Chaoqun L; Dehua Y; Yi S; Yanping J; Luokun X; Qiuping Z; Hui W; Feili G; Boquan J; Youxin J; Jinquan T
Oncogene; 2007 Aug; 26(39):5741-51. PubMed ID: 17369855
[TBL] [Abstract][Full Text] [Related]
18. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness.
Lai HC; Chung WM; Chang CM; Liao PY; Su YT; Yeh CC; Jeng LB; Ma WL; Chang WC
Anticancer Res; 2020 Mar; 40(3):1285-1295. PubMed ID: 32132025
[TBL] [Abstract][Full Text] [Related]
20. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]